BioTech Health X
  • BioTech News
  • BioTech CEO Interviews
  • Contact Us
Archives
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • September 2024
  • August 2024
  • July 2024
  • May 2024
  • April 2024
  • December 2023
  • October 2023
  • August 2023
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • December 2021
  • November 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
BioTech Health X
  • BioTech News
  • BioTech CEO Interviews
  • Contact Us
Subscribe

Browsing Tag

UroGen Pharma Ltd. (URGN)

1 post

Biotech NewsUroGen (URGN) Posts $25.2M Q3 Revenue, Targets $5B Market with UGN-102 Launch

  • BioTech Health X
  • November 17, 2024
UroGen Pharma Ltd. (URGN), a biotechnology company revolutionizing cancer care, announced Q3 2024 revenue of $25.2 million, a…
0 Shares
0
0
0
0
0
0
0
Recent Comments
  • Novavax Announces Robust First Quarter 2024 Results and Strategic Partnerships • BioTech Health X on Novavax and Sanofi Forge $1.2 Billion Alliance to Boost COVID and Flu Vaccine Efforts
  • Thomas Shentz on Cellarity Expands Leadership Team to Continue Evolution of Breakthrough Platform to Encode Biology and Purposefully Create New Drugs
  • Tomasz Michałowski on Exclusive: Cel-Sci CEO Geert Kersten Talks Multikine, FDA Approval, CVM Future
  • Presenters Announced for 2021 William Blair Biotech Conference • BioTech Health X on William Blair Biotech Focus Conference 2021 Panel Schedule
Recent Posts
  • Quantum-Si (QSI) Stock Soars: QSI Can Be the Future of Protein Sequencing
    • February 8, 2025
  • Lan Su, COO of Lakeside Holding, Shares His Vision and Strategies for Charting New Horizons
    • January 27, 2025
  • Voyager Therapeutics (VYGR) Reports $24.6M in Q3 2024 Collaboration Revenues
    • January 19, 2025
Categories
  • BioTech CEO Interviews (9)
  • Biotech Info (1)
  • Biotech News (128)
  • Uncategorized (1)
Author
Hello, I’m
BioTech Health X
Follow
Recent Posts
  • Pathology and Oncology Research Publishes Landmark Phase 3 Study: Multikine Immunotherapy Significantly Improves Survival and Quality of Life in Head and Neck Cancer Patients
  • Aptose Biosciences (APTO) Stock Soars 31.50%: A Penny Stock on the Rise
  • CEL-SCI Corporation: Leading the Future of Cancer Immunotherapy with Multikine®
  • Ginkgo Bioworks (DNA): A Leader in Synthetic Biology Driving Innovation in 2024
  • Hyperfine (HYPR)’s Swoop® Portable MRI: Transforming Emergency Neurological Care
Featured Posts
    • March 24, 2025
    Pathology and Oncology Research Publishes Landmark Phase 3 Study: Multikine Immunotherapy Significantly Improves Survival and Quality of Life in Head and Neck Cancer Patients
    • February 23, 2025
    Aptose Biosciences (APTO) Stock Soars 31.50%: A Penny Stock on the Rise
    • February 20, 2025
    CEL-SCI Corporation: Leading the Future of Cancer Immunotherapy with Multikine®
    • February 8, 2025
    Ginkgo Bioworks (DNA): A Leader in Synthetic Biology Driving Innovation in 2024
    • February 8, 2025
    Hyperfine (HYPR)’s Swoop® Portable MRI: Transforming Emergency Neurological Care
BioTech Health X
Designed & Developed by BioTech Health X
  • About BioTech Health X
  • List of Modern Life Science Technologies
  • Biotechnology Company Directory – List of Major Biotech Companies
  • Contact Us
  • Privacy Policy

Subscribe to
Our Updates

Back to top